Baseline GDF-15 >1800 ng/L was independently associated with increased 10-year total mortality compared to levels <1200 ng/L (HR 1.73; 95% CI 1.02-2.94).
Cohort (n=1,073)
Are baseline concentrations and 12-month changes of GDF-15 associated with subsequent cardiovascular events and total mortality in patients with stable coronary heart disease?
Elevated baseline GDF-15 and >20% increases over 12 months are independently associated with higher 10-year total mortality in patients with stable coronary heart disease.
Hazard Ratio: 1.73 (95% CI 1.02–2.94)
BACKGROUND: This study considered whether baseline concentrations and 12-month changes of growth differentiation factor 15 (GDF-15) are associated with subsequent cardiovascular events (CVEs) and total mortality in patients with stable coronary heart disease. METHODS: Baseline GDF-15 serum concentrations were measured in 1073 participants in a cardiac rehabilitation program (median follow-up 10 years). GDF-15 associations with subsequent CVE and total mortality were evaluated by Cox-proportional hazards models adjusting for well-established cardiovascular risk factors (Model 2), plus N-terminal probrain natriuretic peptide, high-sensitivity (hs) CRP, and hs cardiac troponin T (Model 3). RESULTS: In our study population 84.7% men, mean age 59 years, median baseline GDF-15 1232 ng/L (interquartile range, 916, 1674) we observed 190 CVE and 162 deaths. Compared to participants with GDF-15 1800 ng/L HR 1.73 (1.02-2.94), even in Model 3. The 12-month relative median change was -16.7%. As compared to participants with 12-month relative changes between -20% and 20%, GDF-15 increments >20% were associated with: a) an HR of 1.84 (1.04-3.26) for CVE in Model 2, but found nonsignificant in Model 3; (b) an HR of 2.26 (1.32-3.86) for death even in Model 3. CONCLUSIONS: GDF-15 at baseline is independently associated with subsequent CVE and 10-year total mortality. Twelve-month relative changes remained associated with subsequent CVE when adjusting for well-established cardiovascular risk factors, and with total mortality even after further adjustment for established cardiac biomarkers.
Dallmeier et al. (Fri,) conducted a cohort in stable coronary heart disease (n=1,073). Baseline GDF-15 >1800 ng/L vs. GDF-15 <1200 ng/L was evaluated on total mortality (HR 1.73, 95% CI 1.02-2.94). Baseline GDF-15 >1800 ng/L was independently associated with increased 10-year total mortality compared to levels <1200 ng/L (HR 1.73; 95% CI 1.02-2.94).